0001209191-19-014300.txt : 20190227 0001209191-19-014300.hdr.sgml : 20190227 20190227201916 ACCESSION NUMBER: 0001209191-19-014300 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190225 FILED AS OF DATE: 20190227 DATE AS OF CHANGE: 20190227 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Turner Heather D CENTRAL INDEX KEY: 0001403571 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-30171 FILM NUMBER: 19639972 MAIL ADDRESS: STREET 1: 12481 HIGH BLUFF DRIVE, SUITE 160 CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SANGAMO THERAPEUTICS, INC CENTRAL INDEX KEY: 0001001233 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 680359556 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 501 CANAL BLVD STREET 2: POINT RICHMOND TECH CNTR. CITY: RICHMOND STATE: CA ZIP: 94804 BUSINESS PHONE: 5109706000 MAIL ADDRESS: STREET 1: 501 CANAL BLVD STREET 2: POINT RICHMOND TECH CNTR. CITY: RICHMOND STATE: CA ZIP: 94804 FORMER COMPANY: FORMER CONFORMED NAME: SANGAMO BIOSCIENCES INC DATE OF NAME CHANGE: 20000208 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-02-25 0 0001001233 SANGAMO THERAPEUTICS, INC SGMO 0001403571 Turner Heather D C/O SANGAMO THERAPEUTICS, INC. POINT RICHMOND TECH CTR., 501 CANAL BLVD RICHMOND CA 94804 0 1 0 0 EVP, General Counsel & Sec. Common Stock 2019-02-25 4 A 0 19250 0.00 A 19250 D Stock Option (Right-to-Buy) 9.03 2019-02-25 4 A 0 115500 0.00 A 2029-02-24 Common Stock 115500 115500 D Represents 19,250 shares subject to restricted stock units granted on February 25, 2019 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such date. One-quarter (1/4) of the option shares vest and become exercisable upon completion of one (1) year of service by the Reporting Person measured from the February 25, 2019 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. /s/ Denise Winn, Attorney-in-Fact for Heather Turner 2019-02-27